Table 10.
Activity (preferential for) | Skin | EpiDerm™ | Episkin™ | Episkin™ FTM | SkinEthik™ RHE | Phenion® FT | StrataTest® |
---|---|---|---|---|---|---|---|
AHH (CYP1 family) | 0.24–1.35d | ||||||
EROD (CYP1 family) |
bd-35d 3.0 ± 1.2g |
bd/1.7 ± 0.8f | 7.8 ± 0.4g | 2.6 ± 0.3g | 2.8 ± 0.9g | bd | <1d |
MROD (CYP1A2) | bd to + | bd/0.7 ± 0.3f | |||||
PROD (CYP2B6) | bd to bq | bd/bd | bd | <4d | |||
MFCOD (CYP1/2, especially 2C9) |
bd ~≤0.5g |
bd/bd | ~≤0.5g | ~≤0.5g | ~≤0.5g | ||
BROD (CYP2B/3A) | bd | bd | <1d | ||||
Tolbutamide 4-hydroxylation (CYP2C9) | 0.46 ± 0.05e | ||||||
Bufuralol | bd | ||||||
1-Hydroxylation (CYP2D6) | |||||||
Chlorzoxazone 6-hydroxylation (CYP2E1) | 2.83 ± 0.34e | ||||||
Para-nitrophenol hydroxylation (CYP2E1) | bd/+ | ||||||
Midazolam 1-hydroxylation (CYP3A4) | 2.35 ± 0.23e | ||||||
BQOD (CYP3A) | bd-76 ± 41d | 94 ± 13d/5.5 ± 0.9f | |||||
Erythromycin N-demethylase (CYP3A) | + |
More examples and references in the text
AHH aryl hydrocarbon hydroxylase, phenolic benzo[a]pyrene metabolites determined with 3-hydroxy-benzo[a]pyrene as standard, bd below detection, BROD 7-benzyloxyresorufin O-debenzylase, BQOD benzyloxyquinoline O-dealkylase, ECOD 7-ethoxycoumarin O-dealkylase, EROD 7-ethoxyresorufin O-dealkylase, MFCOD 7-methoxy-4-trifluoromethylcoumarin O-dealkylase, MROD 7-methoxyresorufin O-deethylase, PROD 7-pentoxyresorufin O-dealkylase
aConstitutive; number after slash: induced (highest reported induced activity)
bFor description of the reconstructed human skin models, see Table 1
cPrimary keratinocytes in culture (“NHEC,” “normal human epithelial keratinocytes”)
dpmol/min/mg microsomal protein
epmol/h/mg microsomal protein
fpmol/min/mg intact model protein
gpmol of products/6 h/mg protein (sum of 7,500g supernatant + medium)